

Subjects Screened
N = 194

Screening Failures
N = 23

Subjects Enrolled
into Open-Label
Dose-Optimization
N = 171

Subjects Withdrawn
N = 21

Subjects Completed
N = 150

Adverse Event (3)
Protocol Violation (2)
Withdrew Consent (5)
Lost to Follow-up (4)
Application Site Reactions (4)
Lack of Efficacy (2)
Investigator Decision (1)